Overview

Placebo Controlled, Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAP-001 in Gout Patients

Status:
Completed

Trial end date:
2020-08-30

Target enrollment:

Participant gender:

Summary

This is a Phase II, Multicenter, Randomized, Double-blind, Placebo controlled, Multiple Dose study to evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAP-001 in Gout Patients with Hyperuricemia.

Phase:

Phase 2

Details

Lead Sponsor:

Shanton Pharma Co., Ltd.

Treatments:

Allopurinol